Clovis takes stock as rival Tesaro shines
cancer, Clovis, ovarian cancer, R&D, Tesaro
0 Comment
Oncology firm could make acquisition if ovarian cancer drug approved.
ESMO2016
Cancer market commentary: Roche’s Tecentriq muscles into NSCLC
BMS, breakthrough, cancer, docetaxel, ESMO, kantar, Keytruda, Merck, Opdivo, Roche, Tecentriq, trial
0 Comment
Roche’s PD-L1 drug has generated impressive data in second line lung cancer
Cancer Market Commentary: Keytruda’s triumph not the last word in NSCLC
2016, cancer, development, ESMO, Keytruda, Opdivo, pharma, treatment
0 Comment
Despite Keytruda’s overwhelming victory, it’s not over yet in NSCLC
Some good news for BMS with Opdivo + natural killer cell combination
Bristol-Myers Squibb, cancer, immuno-oncology, Innate Pharma
0 Comment
But BMS dumps combination with Yervoy.
Eye on ESMO: Day Three – Merck & Co. wins big lung cancer battle
breakthrough, chemotherapy, ESMO, lung, Merck, Oncology, pembro, pembrolizumab, small cell, treatment
0 Comment
Merck unveils impressive data on Keytruda, trumping BMS’ Opdivo
Cancer market commentary: 3 highlights from ESMO (Part 1)
AstraZeneca, breast, cancer, ESMO, Faslodex, kantar, Lynparza, Oncology, ovarian, pharma, treatment
0 Comment
Commentary on key cancer data from ESMO by Stephanie Hawthorne
Eye on ESMO: Day 2 – gamechangers take centre stage
breakthrough, clinical trial, ESMO, Lilly, Oncology, ovarian, pharma, trial
0 Comment
Novartis’ phase 3 advanced breast cancer therapy ribociclib shows promise